Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vemurafenib

Vemurafenib Reactions 1680, p332 - 2 Dec 2017 Acute polyneuropathy: case report A 60-year-old man developed acute polyneuropathy during treatment with vemurafenib [route and dosage not stated]. The man, who was diagnosed with BRAF V600E-mutated metastatic melanoma, was started on vemurafenib. He was also taking cobimetinib concomitantly. Four weeks after the start of vemurafenib, he experienced tingling of the feet, which progressed to the fingertips in days. Subsequently, he experienced weakness of hands and legs. Neurological investigation revealed symmetrical distal paresis with trace deep tendon reflexes (DTR) of the arms and absent DTRs of the legs. The distal paresis was noted mainly in legs than that of arms. A distal proportioned loss of vibration sensations and joint position was noted in both legs. MRI ruled out leptomeningeal enhancement and cervical compression. CSF analysis revealed a slight elevation of the total protein level. Other investigations were found to be normal. He was hospitalised. A prompt aggravation of the distal and proximal quadriparesis, neuropathic pain, loss of all DTRs and urinary incontinence was noted during the hospitalisation. He had lost ambulation. Within a week from the onset of symptoms, he required mechanical ventilation. Eventually, the man was started on a 5-day course http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Vemurafenib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017

Vemurafenib

Abstract

Reactions 1680, p332 - 2 Dec 2017 Acute polyneuropathy: case report A 60-year-old man developed acute polyneuropathy during treatment with vemurafenib [route and dosage not stated]. The man, who was diagnosed with BRAF V600E-mutated metastatic melanoma, was started on vemurafenib. He was also taking cobimetinib concomitantly. Four weeks after the start of vemurafenib, he experienced tingling of the feet, which progressed to the fingertips in days. Subsequently, he experienced weakness of...
Loading next page...
 
/lp/springer_journal/vemurafenib-9UTFGwljxG

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39263-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p332 - 2 Dec 2017 Acute polyneuropathy: case report A 60-year-old man developed acute polyneuropathy during treatment with vemurafenib [route and dosage not stated]. The man, who was diagnosed with BRAF V600E-mutated metastatic melanoma, was started on vemurafenib. He was also taking cobimetinib concomitantly. Four weeks after the start of vemurafenib, he experienced tingling of the feet, which progressed to the fingertips in days. Subsequently, he experienced weakness of hands and legs. Neurological investigation revealed symmetrical distal paresis with trace deep tendon reflexes (DTR) of the arms and absent DTRs of the legs. The distal paresis was noted mainly in legs than that of arms. A distal proportioned loss of vibration sensations and joint position was noted in both legs. MRI ruled out leptomeningeal enhancement and cervical compression. CSF analysis revealed a slight elevation of the total protein level. Other investigations were found to be normal. He was hospitalised. A prompt aggravation of the distal and proximal quadriparesis, neuropathic pain, loss of all DTRs and urinary incontinence was noted during the hospitalisation. He had lost ambulation. Within a week from the onset of symptoms, he required mechanical ventilation. Eventually, the man was started on a 5-day course

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.